Compare TFII & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFII | ABVX |
|---|---|---|
| Founded | 1957 | 2013 |
| Country | Canada | France |
| Employees | 24900 | 67 |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.7B |
| IPO Year | 2012 | N/A |
| Metric | TFII | ABVX |
|---|---|---|
| Price | $104.62 | $111.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $126.42 | ★ $130.85 |
| AVG Volume (30 Days) | 358.0K | ★ 770.7K |
| Earning Date | 04-22-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.11 | N/A |
| Revenue Next Year | $5.23 | $0.22 |
| P/E Ratio | $31.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.02 | $4.77 |
| 52 Week High | $127.44 | $148.83 |
| Indicator | TFII | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 40.76 |
| Support Level | $104.63 | $106.37 |
| Resistance Level | $111.99 | $130.20 |
| Average True Range (ATR) | 3.67 | 5.27 |
| MACD | -0.62 | -0.25 |
| Stochastic Oscillator | 36.15 | 11.82 |
TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customer's specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.